GAP-f lead @ WHO. Infectious disease specialist committed to maternal & child health. Foodie, orchids whisperer, traveller and art lover. Tweets are my own
📢 Looking ahead to #WHA78?
We're joining @gap_f_Network’s key side event on 20 May in Geneva:
"Strengthening the Ecosystem for Paediatric Medicines"
🕡 18:30–20:30 CEST | Jardin de Penthes
The new 2025–2030 strategy will also be launched. Don’t miss it.
🔗 Register here: https://t.co/TwwZPbltT4
#BetterMeds4Kids
🌍 "Getting the world back on track: Ending AIDS by 2030 still possible!"
If you're attending #WHA78, join our side event on 19 May, 19:30 CEST.
Stakeholders from IAS, @gnpplus, @PATHtweets & @WHO will explore funding, service delivery & innovations.
🔗 https://t.co/5w7mBznsed
🔍 New study reveals critical gaps in paediatric medicines on national essential medicines lists—especially in LMICs.
Our children’s health is at risk. This is why our collective work is more important than ever.
🚨 It's time for equitable access to #BetterMeds4Kids.
📖 Read more here👇 https://t.co/oJtNNpmWjf
📢Join us at the 78th World Health Assembly for a high-level side event on advancing access to paediatric medicines!
📅 20 May 2025,
🕰️18:30–20:30 CET at Jardin de Penthes, Geneva
🚀Let's strengthen the global ecosystem for #children's #health together!
🔗https://t.co/7LBX26x1sG
#WHA78 #BetterMeds4Kids #GlobalHealth
Millions of kids lack access to age-appropriate meds.
The WHO's @GAP_f_Network is changing that—33 orgs working to deliver #BetterMeds4Kids, especially in LMICs.
Read more in this new paper via @LancetChildAdol 👇
https://t.co/2q3XOv94XR
#Access2Meds
📢Just published in The Lancet Child & Adolescent Health!
"Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas"
💊 A step toward simplifying and standardising paediatric treatment globally.
📄 Read: https://t.co/s6TL0f33yC
#ChildHealth #Bettermeds4kids #GAPf
📢 The Target Product Profiles for priority #paediatric formulations of azithromycin & nitrofurantoin are now available! 📄👇
🔗 https://t.co/XtPYv0v1Zm
Interested #Manufacturers are invited to submit an EOI for product evaluation to #WHO
🔗 Please see https://t.co/SMEgWzf4Z6
#Bettermeds4kids #Antibiotics
📢 Save the date! Join us for our upcoming webinar on Investigating and developing better antibiotics for children: What Can We Do Now and Next?
📅 March 4, 2025
⏰1400-1500 CET
Register here 👉https://t.co/kooDdGrTC5
Global health initiatives have transformed health outcomes for millions of people, especially women, children, and families living with HIV. But our work is not done.
Stand up with us, say ‘Global Health Cannot Wait.’
What happens when HIV services are terminated?
When mothers have access to treatment, their risk of transmitting HIV to their babies is less than 1%. Global health cannot wait!
"Stopping these programs is a death sentence for mothers and children."
Dr. Lynne Mofenson explains what is at risk for the +10,000 pregnant women impacted by the terminations of EGPAF's USAID work in Lesotho, Tanzania, and Eswatini.
📢 Save the date! Join us for our upcoming webinar on Investigating and developing better antibiotics for children: What Can We Do Now and Next?
📅 March 4, 2025
⏰1400-1500 CET
Register here 👉https://t.co/kooDdGrTC5
WHO expresses deep concern about the implications of the immediate funding pause for #HIV programmes in low- and middle-income countries.
These programmes provide access to life-saving HIV therapy to more than 30 million people worldwide.
A funding halt for HIV programmes can put people living with HIV at immediate increased risk of illness and death and undermine efforts to prevent transmission in communities and countries.
Such measures, if prolonged, could lead to rises in new infections and deaths, reversing decades of progress and potentially taking the world back to the 1980s and 1990s when millions died of HIV every year globally, including many in the United States of America.
For the global community, this could result in significant setbacks to progress in partnerships and investments in scientific advances that have been the cornerstone of good public health programming, including innovative diagnostics, affordable medicines, and community delivery models of HIV care.
We call on the Government of the United States of America to enable additional exemptions to ensure the delivery of lifesaving HIV treatment and care.
Read more https://t.co/UWDbvmGGZF
Dolutegravir has transformed HIV treatment for children. The Unitaid-funded PETITE DTG study is now testing innovative, easy-to-administer formulations like dissolvable films, making treatment more accessible for newborns.
Watch the story: https://t.co/drLfcpSV6U
🌍 This #WorldChildrensDay, we are proud to share the GAP-f Phase 2 Progress Report! The 📰highlights progress, challenges, and lessons learned, preparing us for GAP-f's next strategic phase.
Read more here 👉 https://t.co/2NprCSPKpc
Are you attending #TropMed24 this week?
Join the @DNDi symposium on "Advancing research to improve treatment of #NTDs in children" on Friday at 13.45 to learn about our analysis of all registered clinical trials on #children targeting #NTDs@Sarahcharnaud#BetterMeds4Kids
📢Call for public consultation: Target product profile for paediatric formulation of Nitrofurantoin and Azithromycin
📅Deadline: 13 November
Find out more 👉Call for public consultation: Target product profile for paediatric formulation of Nitrofurantoin and Azithromycin (https://t.co/VsuOrwUqug)
🔹 Who can participate? Researchers, healthcare professionals, policymakers, implementers, programme managers and community members involved in child health. 🔹 Deadline: Submit your questions by 24 November 2023. 🔹
This initiative aims to identify key research areas that can drive impactful interventions and improve child health outcomes globally. Your questions will help shape the future of child health by guiding future evidence-informed policies.